SICAGENBSESicagen India LtdCriticalPositive
Announced Wed, 13 May · 17:44 IST

The Board of Directors of the Company in their meeting held on 13.05.2026 i.e. today, has inter-alia considered and approved the Audited Financial Results (both Standalone & Consolidated) ....

Revenue DeclinePat NegativeExceptional ItemResults View source PDF

SICAGEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.3%1-day move
₹54.00
prior close
₹54.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+1.5+1.3-0.3+0.3-2.1-4.6-3.1-2.1+2.8+3.3+0.3-4.0
Up moveDown movePending
AI summary

Sicagen India Ltd reported audited Q4 and FY2025-26 results. Standalone revenue declined 3.4% to Rs 52,027 lakhs with net profit down 11.1% to Rs 1,291 lakhs. However, consolidated revenue grew 9.2% to Rs 97,348 lakhs with net profit up 5.6% to Rs 1,807 lakhs, driven by strong manufacturing segment growth (revenue up 28.2% YoY). The Board recommended a dividend of Rs 1 per share (10%). Auditors issued an unmodified (clean) opinion. Mr. Nandakumar Varma resigned as Whole-time Director effective May 13, 2026, and Mr. Prasanna Joshi was appointed as his replacement for 3 years. M/s. Venkatesh & Co. was appointed as new Internal Auditors for FY2026-27.

Likely market impact

Standalone performance weakness may concern investors, but consolidated growth and clean audit are positives. Director resignation and appointment is a routine governance change with no material concerns.